The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a stabilizing healthcare sector and the search for growth opportunities in biotech, Citi analysts have reaffirmed their positive outlook on Gilead Sciences. The bank maintained its 'Buy' rating on the company's stock (GILD.US) and kept its price target steady at $165. According to reports, this reiteration signals continued institutional confidence in the stock's performance and the company's underlying operational fundamentals.
This valuation comes as Gilead shares trade significantly below analyst targets, with the stock closing at $124.3 on June 15, 2026, per market data. In comparison to sector peers, Amgen's recent results showed a 22% revenue increase in Q1 2024 (per earnings reports), placing competitive pressure on Gilead to strengthen its drug pipeline to maintain investment appeal.
Investors should watch current support levels near the recent low of $122.7 recorded at the close of June 15, 2026. Looking ahead, market sentiment may be influenced by upcoming economic catalysts, following the US CPI which hit 4.2% on June 10, 2026, potentially impacting financing costs for large-cap pharmaceutical firms.
Sign in to access this content
Sign In